Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07556484 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube
A Phase 1 study, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT07556484: Recruiting Phase 1 study, sponsored by Mayo Clinic.
NCT07556484 is a Phase 1 study that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07556484, a Phase 1 study, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the 72-hour pharmacokinetics of emulsified avacopan at a dose of 30 mg twice daily given to up to 6 patients with active severe GPA or MPA with diffuse alveolar hemorrhage (DAH) requiring mechanical ventilation for respiratory support.
Interventions
- DRUG Avacopan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2026-05 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07556484
The ClinicalTrials.gov registry entry for NCT07556484 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avacopan is the first listed.
NCT07556484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07556484 about?
NCT07556484 is a clinical study titled "Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube". The purpose of this study is to determine the 72-hour pharmacokinetics of emulsified avacopan at a dose of 30 mg twice daily given to up to 6 patients with active severe GPA or MPA with diffuse alveolar hemorrhage (DAH) requiring mechanical ventilation for respiratory support.
What is the current status of trial NCT07556484?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2026-05. Estimated completion is 2028-03.
What interventions are being tested in trial NCT07556484?
The interventions under investigation include: Avacopan (DRUG).
Who is sponsoring clinical trial NCT07556484?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.